REPL
Price:
$10.37
Market Cap:
$708.49M
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise cause...[Read more]
Industry
Biotechnology
IPO Date
2018-07-20
Stock Exchange
NASDAQ
Ticker
REPL
According to Replimune Group, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.17. This represents a change of 0.18% compared to the average of -3.16 of the last 4 quarters.
The mean historical PE Ratio of Replimune Group, Inc. over the last ten years is -14.68. The current -3.17 PE Ratio has changed 2.06% with respect to the historical average. Over the past ten years (40 quarters), REPL's PE Ratio was at its highest in in the March 2024 quarter at -2.15. The PE Ratio was at its lowest in in the June 2017 quarter at -22.95.
Average
-14.68
Median
-9.59
Minimum
-42.32
Maximum
-2.38
Discovering the peaks and valleys of Replimune Group, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 168.81%
Maximum Annual PE Ratio = -2.38
Minimum Annual Increase = -59.57%
Minimum Annual PE Ratio = -42.32
Year | PE Ratio | Change |
---|---|---|
2024 | -2.38 | -59.57% |
2023 | -5.90 | -21.47% |
2022 | -7.51 | -56.95% |
2021 | -17.45 | 168.81% |
2020 | -6.49 | -44.34% |
2019 | -11.66 | -50.86% |
2018 | -23.73 | -43.93% |
The current PE Ratio of Replimune Group, Inc. (REPL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.26
5-year avg
-7.95
10-year avg
-14.68
Replimune Group, Inc.’s PE Ratio is greater than Nuvalent, Inc. (-32.10), less than Ventyx Biosciences, Inc. (-0.89), greater than Ascendis Pharma A/S (-12.57), less than United Therapeutics Corporation (14.35), greater than Nuvectis Pharma, Inc. (-4.95), less than Lyra Therapeutics, Inc. (-0.18), less than Kronos Bio, Inc. (-0.58), less than Gossamer Bio, Inc. (-2.55), greater than Kura Oncology, Inc. (-9.19), less than Protagonist Therapeutics, Inc. (14.97), greater than Merus N.V. (-18.45), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), less than Aerovate Therapeutics, Inc. (-0.62), greater than Keros Therapeutics, Inc. (-11.28), greater than Syndax Pharmaceuticals, Inc. (-6.17), greater than Mineralys Therapeutics, Inc. (-4.63), greater than Crinetics Pharmaceuticals, Inc. (-15.40), greater than NewAmsterdam Pharma Company N.V. (-7.25), greater than PureTech Health plc (-4.31),
Company | PE Ratio | Market cap |
---|---|---|
-32.10 | $5.59B | |
-0.89 | $153.35M | |
-12.57 | $6.83B | |
14.35 | $15.38B | |
-4.95 | $115.27M | |
-0.18 | $17.85M | |
-0.58 | $59.36M | |
-2.55 | $205.87M | |
-9.19 | $1.48B | |
14.97 | $2.44B | |
-18.45 | $3.41B | |
-17.73 | $8.19B | |
-0.62 | $54.85M | |
-11.28 | $1.97B | |
-6.17 | $1.63B | |
-4.63 | $558.43M | |
-15.40 | $4.03B | |
-7.25 | $1.48B | |
-4.31 | $487.43M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Replimune Group, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Replimune Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Replimune Group, Inc.'s PE Ratio?
How is the PE Ratio calculated for Replimune Group, Inc. (REPL)?
What is the highest PE Ratio for Replimune Group, Inc. (REPL)?
What is the 3-year average PE Ratio for Replimune Group, Inc. (REPL)?
What is the 5-year average PE Ratio for Replimune Group, Inc. (REPL)?
How does the current PE Ratio for Replimune Group, Inc. (REPL) compare to its historical average?